Alzheimer disease hereditary

New Dosing for Lilly Alzheimer’s Drug Shows Safer Profile

The FDA has approved a safer dosing schedule for Eli Lilly’s Alzheimer’s drug, Kisunla, which could make it more appealing to doctors and patients. The updated schedule reduces the risk of a serious side effect called ARIA-E—brain swelling caused by anti-amyloid drugs. Originally, Kisunla was given in higher doses early on. Now, the drug will

What is COPD, Nucala for COPD treatment

FDA Approves Nucala for COPD Patients with High Eosinophil Levels

The U.S. Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on treatment for adults with chronic obstructive pulmonary disease (COPD) who continue to have flare-ups despite using triple inhaled therapy. Nucala is the first biologic drug specifically approved for COPD patients with an “eosinophilic phenotype”—a group defined by having high levels of

chronic kidney disease, Ozempic kidney disease approval

Ozempic Now Approved for Kidney Disease Treatment

The FDA has approved Novo Nordisk’s drug Ozempic for a new use: reducing the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in adults with Type 2 diabetes and chronic kidney disease (CKD). This approval is significant because Ozempic is now the first drug in its class (GLP-1 receptor agonists) with

Semaglutide weight loss

Novo Nordisk’s Higher-Dose Semaglutide Shows Promising Weight Loss Results

Novo Nordisk is exploring a higher-dose version of semaglutide to enhance weight loss treatments. In a recent phase 3b clinical trial called STEP UP, a 7.2-mg weekly dose of semaglutide helped participants lose an average of 20.7% of their body weight over 72 weeks. This significantly outperformed the 2.4-mg dose marketed as Wegovy, which led

hypertriglyceridemia

Arrowhead Pharmaceuticals’ New Drug Plozasiran Shows Promise in Treating Rare Genetic Disease

Arrowhead Pharmaceuticals announced positive results from its Phase 3 PALISADE study on plozasiran, a new drug for treating familial chylomicronemia syndrome (FCS). FCS is a rare genetic condition that causes extremely high triglyceride levels, leading to serious health issues like acute pancreatitis. Currently, there are no approved treatments for FCS in the United States or

vaccine

US Food and Drug Administration Approves New Pneumococcal Vaccine

Merck & Co.’s new vaccine, CAPVAXIVE (V116), has been approved by the FDA for preventing invasive diseases and pneumonia in adults 18 and older caused by specific strains of the bacteria Streptococcus pneumoniae. This vaccine is particularly aimed at protecting adults over 50 from around 84% of invasive pneumococcal diseases. In several studies, CAPVAXIVE showed

Psoriatic Arthritis Symptoms Causes + Self-Management, psoriasis

Study Results – Amgen Posts Promising Results for Psoriatic Arthritis

Today the Team at JoinAStudy.ca would like to acknowledge the dedicated work of one of our Investigators, Dr. Sabeen Anwar. Dr. Anwar and her team have played a key part in gathering new data to advance the knowledge of patient care for the condition of Psoriatic Arthritis.  The APPRAISE study, a prospective observational investigation conducted